Boehringer Ingelheim Buys ADC Specialist NBE-Therapeutics for US$1.43 B

By Ashish Tripathi & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)

Published: 5 Feb-2021

DOI: 10.3833/pdr.v2021.i2.2590     ISSN: 1756-7874

Section: Mergers & Acquisitions



Reinforcing its commitment to oncology, Boehringer Ingelheim has agreed to acquire NBE-Therapeutics in a deal worth up to US$1...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details